Clinical trials: BCC
Skin Cancer, Mucosal Neoplasm of Oral Cavity
Alpha Radiation Emitters Device for the Treatment of Cutaneous, Mucosal and Superficial Soft Tissue Neoplasia (DaRT)
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia
- Conditions
- Skin Cancer, Mucosal Neoplasm of Oral Cavity, Soft Tissue Neoplasm
- Trial name
- NCT03886181
- Testing
- Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Italy
- Volunteers
- 2 people
- Sponsor
- Alpha Tau Medical LTD.
Advanced Solid Tumors, MSI-H/dMMR Tumors
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors
The purpose of this study is to evaluate the safety and tolerability, pharmacokinetics, and pharmacodynamics of INCB099318 in select solid tumors.
- Conditions
- Advanced Solid Tumors, MSI-H/dMMR Tumors, Cutaneous Squamous Cell Carcinoma, Urothelial Carcinoma, HCC
- Trial name
- NCT04272034
- Testing
- INCB099318
- Where
- 24 sites in United States, Belgium and 5 more
- Volunteers
- 105 people
- Sponsor
- Incyte Corporation
Melanoma (Skin), Non-melanomatous Skin Cancer
Isotretinoin in Preventing Skin Cancer
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Isotretinoin may be effective in preventing the development or recurrence of skin cancer.
- Trial name
- NCT00025012
- Testing
- isotretinoin
- Where
- United States
- Sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Basal Cell Carcinoma
A Study to Assess the Effectiveness and Safety of Vismodegib (Erivedge®) in Participants With Advanced Basal Cell Carcinoma (BCC)
This prospective, observational, cohort study is designed to assess the effectiveness and safety outcomes of vismodegib and to assess actual day-to-day disease and participant management by the physician.
- Trial name
- ROSETT (NCT02371967)
- Testing
- Vismodegib
- Where
- 4 sites in Sweden
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
Skin Cancer, Complication
Complications and Recurrences After Mohs Micrographic Surgery and Slow Mohs
Mohs micro-graphic surgery (Mohs) is a tissue-sparing, surgical treatment for different types of skin cancer (e.g. basal cell carcinoma, squamous cell carcinoma, lentigo maligna (melanoma).
- Conditions
- Skin Cancer, Complication, Complication of Surgical Procedure, Complication,Postoperative
- Trial name
- NCT06014619
- Testing
- Mohs surgery, Slow Mohs surgery
- Where
- Netherlands
- Volunteers
- 500 people
- Sponsor
- Maastricht University Medical Center
Basal Cell Carcinoma
Treatment of Nodular Basal Cell Carcinoma (BCC) With Imiquimod 5% Cream After Curettage
To assess the efficacy of treating a nodular basal cell carcinoma with imiquimod cream after initial treatment with curettage
- Trial name
- NCT00314756
- Testing
- imiquimod
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Wake Forest University
Carcinoma, Basal Cell
Basal Cell Carcinomas Treated With Ablative Fractional Laser and Ingenol Mebutate
A prospective clinical, uncontrolled, open-label, explorative phase 2a trial on patients with histologically-confirmed superficial and nodular basal cell carcinoma (BCC).
- Trial name
- NCT03569345
- Testing
- AFXl-assisted ingenol mebutate delivery
- Where
- Denmark
- Volunteers
- 20 people
- Sponsor
- Merete Haedersdal
Basal Cell Carcinoma, Squamous Cell Carcinoma
Effect of the Subconscious on Mohs Micrographic Surgery
The goal of this study is to determine if relaxation therapy improves patient satisfaction with Mohs micrographic surgery.
- Trial name
- NCT00374062
- Testing
- relaxation therapy 1, relaxation therapy 2, relaxation therapy 3
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Northwestern University
Skin Cancer, Mucosal Neoplasm of Oral Cavity
Retreatment With Intratumoral Diffusing Alpha Radiation Emitters
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia
- Conditions
- Skin Cancer, Mucosal Neoplasm of Oral Cavity, Soft Tissue Neoplasm
- Trial name
- NCT04540588
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Israel
- Volunteers
- 2 people
- Sponsor
- Alpha Tau Medical LTD.
Autoimmunity, Melanoma
How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes
The purpose of this research study is to examine the relationship between the microbiota (microscopic organisms) in the gut and the activity of the immune system during skin cancer immunotherapy.
- Conditions
- Autoimmunity, Melanoma, Merkel Cell Carcinoma, Squamous Cell Carcinoma of the Skin
- Trial name
- MINING (NCT03370861)
- Testing
- Immunotherapy
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Washington University School of Medicine
Carcinoma, Basal Cell
Laser Treatment of Basal Cell Carcinoma Under Imaging Guidance
This pilot study will examine the treatment of basal cell carcinoma (BCC) with laser technology under the guidance of imaging modalities to assist with surgical excision, including optical coherence tomography imaging (OCT) and…
- Trial name
- NCT05138328
- Testing
- Treatment of basal cell carcinoma with Nd:YAG laser under imaging guidance of optical coherence tomography (OCT)
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- Henry Ford Health System
Cancer
Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer
RATIONALE: Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00499733
- Testing
- cyclophosphamide, Cryoablation
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Head and Neck Cancer
MRI Mapping in Planning Radiation Therapy to the Base of Skull and Brain in Patients With Nonmetastatic Head and Neck Cancer
RATIONALE: Diagnostic procedures, such as specialized types of magnetic resonance imaging (MRI), may help in planning radiation therapy that does less damage to normal tissues.
- Trial name
- NCT00984074
- Testing
- blood-oxygen-level-dependent functional magnetic resonance imaging, diffusion tensor imaging, dynamic contrast-enhanced magnetic resonance imaging
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Carcinoma, Basal Cell
HIFU for Treatment of Non-nodular and Recurrent BCC
The overall objective of this study is to demonstrate the safety and efficacy of removal of Basal Cell Carcinoma (BCC) using a new investigational equipment based on high-intensity focused ultrasound.
- Trial name
- BCC-HIFU2101 (NCT05133427)
- Testing
- TOOsonix system ONE-M
- Where
- 2 sites in Denmark
- Volunteers
- 28 people
- Sponsor
- Joergen Serup
Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma
IFx-Hu2.0 for the Treatment of Patients With Skin Cancer
One hundred patients will receive IFx-Hu2.0 on an outpatient basis at a single time point in a single lesion. These patients will be assessed for any immediate adverse reactions and at Week 4 (Day 28+/-5 days) for any delayed…
- Trial name
- NCT04925713
- Testing
- IFx-Hu2.0
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- TuHURA Biosciences, Inc.
Skin Cancer, Mucosal Neoplasm of Oral Cavity
Alpha Radiation Emitters Device (DaRT) for the Treatment of Cutaneous, Mucosal or Superficial Soft Tissue Neoplasia
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia
- Conditions
- Skin Cancer, Mucosal Neoplasm of Oral Cavity, Soft Tissue Neoplasm
- Trial name
- NCT04534127
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Israel
- Volunteers
- 56 people
- Sponsor
- Alpha Tau Medical LTD.
Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
This phase I trial is studying the side effects and best dose of erlotinib hydrochloride when given together with cetuximab and to see how well they work in treating patients with advanced gastrointestinal cancer, head and neck…
- Conditions
- Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
- Trial name
- NCT00397384
- Testing
- cetuximab, erlotinib hydrochloride, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- National Cancer Institute (NCI)
Basal Cell Carcinoma
Checking Wether the m-ALA Cream Could Mark Correctly the Borders of BCC's Tumors
Correlation between Mohs surgery and microscopic fluorescence photometry in determination of histological borders in Basal Cell Carcinoma .
- Trial name
- NCT00449358
- Testing
- apply methyl-ALA cream
- Where
- Israel
- Volunteers
- 32 people
- Sponsor
- Assuta Hospital Systems
Basal Cell Carcinomas
Vismodegib in Basal Cell Carcinomas (BCC) Chemoprevention
This study is a single site double blinded Phase II study to evaluate the chemopreventative effectiveness of vismodegib in the treatment of subjects at high risk for developing basal cell carcinomas (BCC).
- Trial name
- NCT02067104
- Testing
- Vismodegib
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- University of Arizona
Basal Cell Carcinoma
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) in Patients With Advanced Basal Cell Carcinoma
This is a Phase II, single-arm, two-cohort multicenter clinical trial evaluating the efficacy and safety of vismodegib (GDC-0449) in patients with advanced basal cell carcinoma.
- Trial name
- NCT00833417
- Testing
- Vismodegib 150 mg
- Where
- 36 sites in United States, Australia and 4 more
- Volunteers
- 104 people
- Sponsor
- Genentech, Inc.